Per the DART-filed annual figures, revenue went from KRW 17.3 billion in 2023 to KRW 20.6 billion in 2024 (up 19.0% year on year) and KRW 20.8 billion in 2025 (up 0.9%), rising two years in a row from 2024 to 2025.
Operating profit went from KRW 719 million in 2023 to KRW 1.46 billion in 2024 (up 102.9%) and then fell to KRW 297 million in 2025 (down 79.7%). The operating margin was 4.2% in 2023, 7.1% in 2024 and 1.4% in 2025, with 2024 the highest of the three years.
Hana Securities attributed the 2025 weakness to a temporary drop in orders after drug-price policy changes, and the company said customer orders slowed after the government's drug-pricing reform proposal was announced in November 2025 and demand recovered after the reform was finalized in March 2026.
Net income attributable to controlling shareholders moved from a net loss of KRW 721 million in 2023 and a net loss of KRW 1.18 billion in 2024 (losses continued and widened) to net income of KRW 822 million in 2025, a turn to profit.
Net income including non-controlling interests was reported as a net loss of KRW 721 million in 2023, a net loss of KRW 1.18 billion in 2024 and net income of KRW 822 million in 2025. Operating cash flow was KRW 9.26 million in 2023, KRW 2.65 billion in 2024 and KRW 2.39 billion in 2025.
At the end of 2025, total equity was KRW 30.1 billion, of which KRW 30.1 billion was attributable to controlling shareholders, and total liabilities were KRW 5.62 billion; the debt ratio fell from 53.7% in 2023 to 28.5% in 2024 and 18.7% in 2025.
Quarterly, operating profit was KRW 0.71 million in the third quarter of 2025 on revenue of KRW 4.52 billion; the fourth quarter swung to an operating loss of KRW 454 million on revenue of KRW 5.01 billion (up 10.9% from the prior quarter).
The first quarter of 2026 brought revenue of KRW 3.18 billion (down 36.5% from the prior quarter) and an operating loss of KRW 347 million. The second quarter returned to operating profit of KRW 239 million on revenue of KRW 6 billion (up 88.6% from the prior quarter).
The third quarter of 2026 recorded revenue of KRW 4.39 billion (down 2.7% year on year) and an operating loss of KRW 228 million, a return to losses.
Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, net losses attributable to controlling shareholders totaled KRW 695 million.